Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Dentresangle
C
C
CERMEP Cyclotron Unit, Hôpital Neurologique Pierre Wertheimer, Lyon, France.
Veyre
L
L
Le Bars
D
D
Pierre
C
C
Lavenne
F
F
Pollak
P
P
Guerin
J
J
Froment
J C
JC
Brousolle
E
E
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D001931:Brain Mapping; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects; D002250:Carbon Radioisotopes; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000503:physiopathology; D004295:Dihydroxyphenylalanine; D004338:Drug Combinations; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D020891:Raclopride; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*; D014055:Tomography, Emission-Computed
D000978:Antiparkinson Agents; D002250:Carbon Radioisotopes; D004338:Drug Combinations; D005462:Fluorine Radioisotopes; D017448:Receptors, Dopamine D2; C009265:carbidopa, levodopa drug combination; D020891:Raclopride; D007980:Levodopa; D004295:Dihydroxyphenylalanine; D002230:Carbidopa